Ownership history in Bellevue Group AG · 7 quarters on record
This page tracks every 13F SEC filing in which Bellevue Group AG reported a position in MOONLAKE IMMUNOTHERAPEUTICS (MLTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | ADDED | 35,052 | +32,052 | +1068.4% | 0.01% | $251K | $7.17 |
| 2025 Q2 | UNCHANGED | 3,000 | — | 0% | 0.00% | $142K | $47.20 |
| 2025 Q1 | REDUCED | 3,000 | -1,400 | -31.8% | 0.00% | $117K | $39.07 |
| 2024 Q4 | UNCHANGED | 4,400 | — | 0% | 0.00% | $238K | $54.15 |
| 2024 Q3 | UNCHANGED | 4,400 | — | 0% | 0.00% | $222K | $50.42 |
| 2024 Q2 | UNCHANGED | 4,400 | — | 0% | 0.00% | $193K | $43.97 |
| 2024 Q1 | INITIATED | 4,400 | — | — | 0.00% | $221K | — |
As of 2025 Q4 — sorted by position size